Orlistat

Visa No.: 893100609424

Product: Orlistat Stada 120 mg

API: Orlistat

Product Category: VMS & Weight Control

Version approved leaflet: 33625e/QLD-ĐK_19/09/2025

INDICATIONS

Orlistat is indicated as an adjunct to a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) ≥ 30 kg/m², or overweight patients (BMI ≥ 28 kg/m²) with associated risk factors (such as hypertension, diabetes mellitus, or dyslipidaemia).
Treatment with orlistat should be discontinued after 12 weeks if the patient has not achieved a minimum weight loss of 5% of initial body weight.
 

DOSAGE AND ADMINISTRATION

Method of administration
The recommended dose of orlistat is one 120 mg capsule, taken with water immediately before, during, or up to one hour after each main meal.
If a meal is occasionally missed or contains no fat, orlistat should not be taken..

Dosage

Adults:
120 mg three times daily. Doses exceeding 120 mg three times daily do not provide additional benefit.

Special populations
The effects of orlistat in patients with hepatic and/or renal impairment, in children, and in the elderly have not been adequately studied.
Orlistat is not indicated for use in children.

CONTRAINDICATIONS

• Hypersensitivity to orlistat or to any of the excipients
• Chronic malabsorption syndrome
• Cholestasis
• Breastfeeding
   

WARNINGS AND PRECAUTIONS

Read the instructions for use carefully before use.
If further information is required, consult a physician or pharmacist.
Keep out of reach of children.